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Abstract
Burning mouth syndrome (BMS) is defined as a burning sensation of the oral mucosa, in the absence of specific 
oral lesions. The underlying etiology remains unclear. Peripheral alterations may be related to the density or reactive 
capacity of the oral mucosal membrane receptors - these being largely influenced by BMS-related risk factors such 
as stress, anxiety, the female gender, climacterium and advanced age. The present study compiles the cases of BMS 
induced by drugs reported in the literature, and attempts to draw a series of conclusions. A search was conducted 
in the PubMed® database using the following key words: burning mouth syndrome, drug-induced, antihypertensive 
and chemically-induced. The search was carried out in April 2007. The literature yielded clinical cases in which oral 
burning sensation is described after the administration of drugs belonging to different therapeutic groups: antire-
trovirals, antiseizure drugs, hormones and particularly antihypertensive medication. Curiously, among the different 
types of antihypertensive drugs, BMS was only associated with those compounds that act upon the angiotensin-renin 
system.
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The etiology underlying burning mouth syndrome (BMS) 
remains uncertain. The disorder is characterized by a 
burning or itching sensation preferentially located at the 
tip and sides of the tongue, lips and anterior palate, in the 
absence of evidence of oral mucosal pathology (1), and 
sometimes associated with taste alterations and dry mouth 
(2,3). The manifestations of BMS are usually bilateral, but 
in some cases may prove unilateral.
The syndrome is more common in women than in men - 
the peak prevalence corresponding to females in the fourth 
to sixth decades of life (3,4).
The diagnosis of BMS requires careful evaluation of the 
symptoms, with due consideration of a series of inclusion 
criteria (5): (a) burning sensation located in some area 
of the oral mucosa; (b) persistence of the manifestations 
for at least 4-6 months; (c) continuous burning sensation 
throughout the day, or with increased intensity towards 
the afternoon-evening; (d) infrequent associated sleep 
disturbances; and (e) symptoms relief  upon eating or 
drinking.
Cerchiari (6) classified BMS according to the associated 
risk factors: idiopathic, psychogenic, local and systemic. 
Among the psychogenic risk factors, mention should be 
made of psychopathological processes such as anxiety, 
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depression and certain phobias. The local factors in 
turn comprise infectious processes, allergic reactions 
and irritative phenomena, while the systemic etiological 
factors include alterations in salivary secretion, endocrine 
disorders, neurological alterations, nutritional factors, and 
drug substances.
Antihypertensive agents are the drugs most often as-
sociated with the appearance of symptoms compatible 
with BMS. Likewise, among the different types of  an-
tihypertensive drugs, those related to the appearance of 
burning mouth sensation are compounds that act upon 
the angiotensin-renin system.
Among the drugs reported to induce manifestations similar 
to those of BMS, mention should be made of efavirenz (7), 
an antiretroviral agent that inhibits reverse transcriptase of 
the human immunodeficiency virus (HIV); the antiseizure 
drug clonazepam(8), which paradoxically is the compound 
offering the best results in the management of BMS, with 
a remission rate of up to 40% (9-11); hormone replace-
ment therapy (HRT)(12); the antidepressants fluoxetine, 
sertraline and venlafaxine(13); and a broad range of 
antihypertensive agents, including captopril, enalapril, 
lisinopril, eprosartan and candesartan (14-19).
Of the global cases of drug-induced BMS, 33% were seen 
to be dose-dependent phenomena, since the burning sen-
sation appeared on elevating the drug dose in search of 
increased therapeutic efficacy. No relationship was found 
between the duration of treatment and appearance of the 
symptoms.
Some cases have been associated with risk factors such 
as depression, anxiety or menopause (20-22). Moreover, 
in all cases corresponding to females, the latter were of 
postmenopausal age.
Of the 9 documented cases of BMS induced by antihy-
pertensive drugs, a little over half  were women. Bergdahl 
et al. (3) reported that for every male diagnosis of BMS, 
3.44 women are diagnosed with the disorder. In the present 
review, the female predominance in BMS was 1.25/1. The 
three documented cases associated with captopril corres-
ponded to women, while the three cases associated with 
enalapril corresponded to males. 
A number of authors have found antihypertensive agents 
to be the drugs most often associated with the appearan-
ce of symptoms compatible with BMS (23-25). This is 
supported by the scientific literature searches of drug-
induced cases of BMS (Table 1).
At present, arterial hypertension can be treated with a 
broad range of drugs belonging to 5 therapeutic categories 
or groups: diuretics, beta-adrenergic receptor blockers, 
angiotensin-converting enzyme inhibitors (ACEIs), and 
angiotensin II receptor blockers or antagonists (ARBs 
or ARAII drugs)(26).
Curiously, the only types of  antihypertensive drugs 
associated with BMS-compatible symptoms are those 
compounds that act upon the angiotensin-renin system, 
i.e., ACEIs (captopril, enalapril and lisinopril) and ARAII 
drugs (eprosartan and candesartan)(27,28).
The renin-angiotensin system plays a key role in the 
regulation of blood pressure. It consists of a cascade of 
enzyme reactions that lead to the formation of angiotensin 
II (Figure 1). The first reaction is catalyzed by renin, and 
consists of the transformation of angiotensinogen into 
angiotensin. This is followed by the angiotensin-converting 
enzyme (ACE)-mediated transformation of angiotensin I 
into angiotensin II, which is the biologically active mo-
lecule (29,30).
AUTHOR DRUG ACTIVITY SEX AGE POSOLOGY TIME 1
Borras-Blasco et al (7) Efavirenz Antiretroviral F 42 600 mg/24h 2 weeks
Culhane et al (8) Clonazepam Anxiolytic F 52 0.5 mg/12h 4 weeks
Levenson (13) Fluoxetine Antidepressant F 56 30 mg/24h 2 weeks
Levenson (13) Sertraline Antidepressant F 56 100 mg/24h not stated
Levenson (13) Venlafaxine Antidepressant F 56 not stated not stated
Triantos et al (14) Enalapril Antihypertensive M 50 20 mg/24h 6 months
Brown et al (17) Enalapril Antihypertensive M 72 10 mg/12h 1 year
Vlasses et al (19) Enalapril Antihypertensive M 54 20 mg/12h 7 days
Vlasses et al (19) Captopril Antihypertensive F 53 25 mg/8h 6 days
Vlasses et al (19) Captopril Antihypertensive F 64 50 mg/8h 9 weeks
Brown et al (17) Captopril Antihypertensive F 54 not stated 7 years
Savino et al (18) Lisinopril Antihypertensive F 74 10 mg/24h 2 months
Chen et al (15) Candesartan Antihypertensive M 46 4 mg/24h 6 months
Castells et al (16) Eprosartan Antihypertensive F 48 600 mg/24h 3 weeks
Table 1. Description of cases of burning mouth syndrome induced by drugs.
1 Time to appearance of burning mouth syndrome after start of treatment
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The ACEIs act upon the enzymatic cascade of the renin-
angiotensin system, inhibiting ACE and thus preventing 
the transformation of angiotensin I into angiotensin II. In 
turn, the ARAII drugs act upon a later step in the cascade, 
blocking angiotensin II receptor activation. These drugs, 
which show highly varied chemical structures, ultimately 
prevent the formation and interaction of angiotensin II 
with its receptors, thus blocking the activity of the former 
(Figure 1). 
by intermittent pain in unusual locations such as the floor of 
the mouth, and is associated with the presence of allergens 
such as preservatives and additives.
Considering that antihypertensive drugs which act upon 
the renin-angiotensin system have been associated with 
BMS-like symptoms, and in view of the heterogeneity 
of the described cases of BMS, the underlying etiology 
in some situations may involve an anomaly of the renin-
angiotensin system that blocks angiotensin II activity and 
causes burning sensation of the oral mucosa. It would be 
interesting to search for markers of this enzymatic ano-
maly in order to determine its prevalence and relationship 
to the clinical manifestation of BMS.
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